Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough competition ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $50.28. Olson covers the Healthcare sector ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults ...

Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Cystic fibrosis specialist Vertex Pharmaceuticals is becoming a more diverse drug developer. Moderna's innovative platform should allow it to launch more groundbreaking vaccines in the future. Both ...